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nation vehicles that elicit protective T cell immunity in disease
models. Dendritic cells (DCs) acquire antigen at sites of vacci-
nation and migrate to draining lymph nodes, where they prime
vaccine-speciﬁc T cells. The potency with which LVs activate
CD8+ T cell immunity has been attributed to the transduction
of DCs at the immunization site and durable presentation of
LV-encoded antigens. However, it is not known how LV-en-
coded antigens continue to be presented to T cells once directly
transduced DCs have turned over. Here, we report that LV-en-
coded antigen is efﬁciently cross-presented by DCs in vitro. We
have further exploited the temporal depletion of DCs in the
murine CD11c.DTR (diphtheria toxin receptor) model to
demonstrate that repopulating DCs that were absent at the
time of immunization cross-present LV-encoded antigen to
T cells in vivo. Indirect presentation of antigen from trans-
duced cells by DCs is sufﬁcient to prime functional effector
T cells that control tumor growth. These data suggest that
DCs cross-present immunogenic antigen from LV-transduced
cells, thereby facilitating prolonged activation of T cells in the
absence of circulating LV particles. These are ﬁndings that
may impact on the future design of LV vaccination strategies.Received 5 July 2016; accepted 11 November 2016;
http://dx.doi.org/10.1016/j.ymthe.2016.11.001.
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Lentiviral vectors (LVs) are efﬁcient vaccination vehicles for the de-
livery of target antigens in vivo, and have been widely used as immu-
nization vectors to activate protective T cell immunity in pre-clinical
models of infectious disease and cancer.1 In particular, cutaneous
vaccination with LV-expressing tumor-associated antigens is highly
effective at reducing the tumor burden in therapeutic models of mel-
anoma.2–5 Third-generation LVs have been engineered from parental
HIV-1 virions to enhance safety and expression of the inserted trans-
gene.6,7 All non-essential viral accessory proteins have been deleted
from the vectors, and deletion of part of U3 in the 30 long terminal
repeat prevents production of new packaged LV particles by the
transduced cell. These modiﬁcations have resulted in the use of
LVs that produce undetectable amounts of replication-competent
particles in sensitive screening assays8 and that are being tested for
biosafety for clinical trials.9,10 The persistence of viral antigens has504 Molecular Therapy Vol. 25 No 2 February 2017 ª 2016 The Author(s)
This is an open access article under the CC BY license (http://creativecbeen suggested to be key to their function as vaccine vectors.11 We
questioned how immunization with short-lived replication-incompe-
tent viral particles could be reconciled with the long-term immunity
elicited by LVs in vivo.
Dendritic cells (DCs) are antigen-presenting cells (APCs) that are
required to prime and orchestrate T cell immunity.12 Upon uptake
of viruses, infected DCs may directly present viral antigens in the
context of major histocompatibility complex (MHC) class I molecules
to CD8 T cells, but also cross-present exogenous antigens from dying
cells.13 The potency of LV vaccination has been repeatedly attributed
to the direct transduction of DCs at the injection site and to the dura-
bility of the LV-encoded antigen reservoir in vivo.1,11 Cutaneous
immunization with LVs results in the transduction of skin DCs
that migrate to draining lymph nodes (LNs) and prime naive
T cells,11,14,15 and we have previously shown that DCs are required
for presentation of LV-encoded antigens to CD8+ T cells in vivo.16 Af-
ter cutaneous vaccination, free LV particles will be rapidly eliminated,
but a depot of LV-encoded antigen persists, and may even accumu-
late, in transduced cells at the site of injection and in draining LNs
for more than 3 weeks after immunization.11,15,17 This is well beyond
the lifespan of dermal and LN DCs,18,19 and it is not known which
cells present LV-encoded antigen to T cells once directly transduced
DCs have been replaced. Removal of the injection site 5, but not 10,
days after immunization prevents T cell priming, suggesting that
directly transduced migrating DCs are required within the ﬁrst
5 days post-immunization, but other cells present LV-encoded anti-
gens to T cells after this time.15
In this study, we have investigated whether cross-presentation of
LV-encoded antigen from transduced cells by DCs is sufﬁcient for
the generation of functional, protective effector T cell responses after
immunization with LV. We demonstrate that DCs indirectly acquire.
ommons.org/licenses/by/4.0/).
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Figure 1. DCs Cross-Present LV-Encoded Antigen
In Vitro
(A) Representative histogram overlay showing the
expression of MHC I (H-2Kb) on BM-DCs derived from
WT or b2M/ mice. (B) BM-DCs were transduced with
LV-Thy1.1-Ii:OVA at a multiplicity of infection of 5–10 on
day6 of culture. Forty-eight hours later, cellswere analyzed
for the frequency of transduced cells. Representative dot
plots show the percentage of Thy1.1+ CD11c+ cells in a
gated live cell population. Data are representative of less
than five independent experiments. (C) To test direct
presentation of LV-encoded antigen, we co-cultured
2.5  103 LV-transduced WT DCs with CFSE-labeled
OT-I cells. Alternatively, 2.5 103 LV-transduced b2M/
BM-DCs were irradiated and incubated with or without
2.5  104 WT BM-DC for 24 hr before co-culture with
T cells. The representative histograms show CFSE on
gated live OT-I cells that were either indirectly (top) or
directly (middle) primed by DCs. The bottom histogram
shows 2.5  103 LV-transduced b2M/ BM-DCs alone
with T cells. Percentages show the frequency of cells
in the barred gate. (D) Summary graph showing the
percentage ± SEM of dividing OT-I cells in direct or cross-
presentation assays. For the cross-presentation, titrated
numbers of b2M/ BM-DCs were cultured with constant
numbers (2.5 104) ofWTBM-DCs. Data are pooled from
four independent experiments; p = 0.0009, two-way
ANOVA. (E) Representative histograms showing CFSE on
liveOT-I cells fromcultures similar to thosedescribed in (C),
but with b2M/ BM-macrophages (MF). Data are repre-
sentative of two independent experiments. (F) GFP-LV
particles were treated by irradiation and culture for 48 hr
before incubation with 3T3 T cells. The graph shows the
percentage±SEMof 3T3 cells expressingGFP3 or 5 days
after addition of the LV. Control LV was defrosted imme-
diately before addition to the culture. Data are pooled from
two independent experiments.
www.moleculartherapy.organd cross-present LV-encoded antigen in an immunogenic form to
activate CD8+ T cells. These data suggest an important mechanism
that may contribute to the potency of LVs as vaccination agents.
RESULTS
LV-Derived Antigen Is Efficiently Cross-Presented by DCs
In initial experiments we investigated whether DCs cross-presented
antigen from LV-transduced cells. To this end, we tested the process-
ing and presentation of exogenous LV-encoded antigen to CD8+
T cells using an in vitro model of cross-presentation of cell-associated
antigen. Bone-marrow (BM)-derived DCs from MHC class I (b2M)-
deﬁcientmice (Figure 1A), which cannot directly present LV-encoded
antigens to CD8+ T cells, were transduced with LVs expressing the
C terminus of themodel antigenOvalbumin (OVA) fused to invariant
chain (LV-Ii:OVA),20 irradiated, and co-cultured with wild-type
(WT) DCs and OVA-speciﬁc (OT-I) T cells. Forty-eight hours after
transduction of differentiated BM-DCs with LV at a multiplicity of
infection of 5–10, 8.6% ± 1.56% (SEM) of live cells were transduced
(n = 7 cultures from four independent experiments). This relatively
low transduction efﬁciency most likely reﬂects the challenge in trans-
ducing fully differentiatedDCs, similar to those that would be found atthe injection site. There was no difference in the efﬁciency of transduc-
tion between WT and b2M/ BM-DCs (Figure 1B). Transduction
with LVs induced maturation of a proportion of BM-DCs based on
increased surface expression of CD86 (data not shown). Transduced
cells were subsequently washed and irradiated before co-culture
with WT BM-DCs. Figures 1C and 1D show that CD8+ OT-I cells
were efﬁciently primed, both as a result of direct presentation by trans-
duced WT BM-DCs and cross-presentation on uptake of transduced
b2M/ BM-DCs by WT DCs. LV-transduced b2M/ BM-DCs did
not activate T cell proliferation in the absence ofWTDCs (Figure 1C).
Processing of cellular antigen for loading onto MHC I molecules is a
relatively inefﬁcient process and requires higher concentrations of an-
tigen than is needed for direct presentation assays. Our data demon-
strated that cross-presentation of LV-encoded antigens was rapidly
lost when fewer than 2,500 b2M/ BM-DCs were cultured with
WT cells. This equated to approximately 215 transduced cells.
In vivo, long-lived macrophages or stromal cells are likely to be a
source of persistent LV-encoded antigen. To test whether these pop-
ulations could act as cellular LV-encoded antigen donors for DCs, we
transduced BM-derived macrophages from b2M/ and co-culturedMolecular Therapy Vol. 25 No 2 February 2017 505
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Figure 2. Temporal Depletion of CD11c+ DCs In Vivo
Established CD11c.DTR/C57BL/6 chimeras either received continuous injections
of DT every 2–3 days over a period of 2 weeks or received three injections of DT for
the first week followed by PBS for the second week. (A) Representative dot plots
showing CD11c+ GFP+ DCs in the spleens of chimeras that have received contin-
uous (no DC) or short (repopulating DC) DT treatment. Dot plots are pre-gated
on live cells. (B) Summary bar graphs showing the percentage (left) and number
(right) ± SEM of live CD11c+ GFP+ in the spleens of chimeras injected with PBS
(n = 11) or a continuous (no DC, n = 5) or short (repopulating DC, n = 10) course of
DT. Frequency: PBS versus no DCs: p = 0.0005; repopulating DCs versus no DCs:
p = 0.0007. Numbers: PBS versus no DCs: p = 0.0009; repopulating DCs versus no
DCs: p = 0.0007 (Mann-Whitney test). *** p < .001. Data are pooled from four in-
dependent experiments.
Molecular Therapythese cells with WT-DCs. Figure 1E shows that LV-encoded oval-
bumin may also be cross-presented from macrophages. We were un-
able, however, to detect cross-presentation when the ﬁbroblast
3T3 cell line was used (data not shown). It is unclear why this is
the case but may be because of the fact that immortalized cells lines
are more resistant to cell death than primary cells, and therefore
less likely to stimulate cross-presentation by DCs.21 Alternatively, it
has recently been suggested that antigen uptake by the donor cells
may directly regulate cross-presentation of that antigen.22
Finally, to ensure that free “infectious” LV particles were not trans-
ferred with b2M/ BM-DCs, we tested the transduction efﬁciency
of LVs that had been irradiated and cultured at 37C according to
our cross-presentation protocol. Figure 1F shows that viable LVs do
not persist after this treatment.
Therefore, together these data demonstrate that cell-associated
LV-encoded antigen may be cross-presented to CD8+ T cells upon
uptake of transduced cells by DCs.
Temporal Depletion of DCs Using the CD11c.Diphtheria Toxin
Receptor Model
To investigate whether LV-encoded antigens were cross-presented
in vivo, we exploited the temporal nature of DC depletion in the506 Molecular Therapy Vol. 25 No 2 February 2017CD11c.DTR (diphtheria toxin receptor) model. In this model,
CD11c+ conventional DCs are inducibly depleted upon injection
of diphtheria toxin (DT) because of the engineered expression of a
high-afﬁnity DT receptor (DTR). To allow for long-term depletion
of DCs, we generated CD11c.DTR/C57BL/6 syngeneic chimeras
in which the transgene was restricted to the hematopoietic system.16
DCs are repopulated from CD11c.negative precursors within 72 hr of
injection of DT.23,24 Therefore, to deplete DCs throughout experi-
ments, we continuously injected established chimeras with DT every
2–3 days for 2 weeks. DT treatment resulted in an average depletion of
88.25% of DCs. Alternatively, chimeras received three injections of
DT, to deplete DCs for the ﬁrst week, followed by PBS. This allowed
complete repopulation of the DC niche 1 week later (Figures 2A and
2B). Manipulation of conventional DCs in this way provided a power-
ful model with which to investigate whether repopulating DCs, which
had not been directly transduced by LV, could detect and cross-pre-
sent LV-encoded antigens to T cells in vivo.
DCs in Skin-Draining LNs Cross-Present LV-Encoded Antigens
to CD8+ T Cells
We have previously established an immunization model in which
subcutaneous (s.c.) injection of a low dose of LV particles (14 ng
reverse transcriptase [RT] activity) elicits robust, protective effec-
tor and memory T cell immunity.16 It has previously been shown
that directly transduced DCs prime T cell immunity to cutaneous
LVs within the ﬁrst 5 days post-immunization.15 Therefore, to test
whether cross-presentation of LV-encoded antigen by DCs was sufﬁ-
cient to prime CD8 T cells in vivo, we designed experiments in which
DCs were selectively absent at vaccination and during this period.
CD11c.DTR/C57BL/6 established chimeras were immunized with
LV-Ii:OVA and either depleted of DCs for the duration of the exper-
iment or DCs were selectively depleted at the point of, and 5 days af-
ter, vaccination (Figure 3A). Presentation of LV-encoded antigen was
visualized by adoptive transfer of carboxyﬂuorescein succinimidyl
ester (CFSE)-labeled, OVA-speciﬁc CD8+ (CD45.1+) OT-I cells
from days 8–11 post-injection of LV-Ii:OVA. Figure 3B shows that
repopulating DCs, which were absent at the time of immunization,
presented LV-encoded antigen to OVA-speciﬁc T cells as efﬁciently
as DCs in non-depleted control mice. T cells primed by re-emerging
DCs also accumulated in the LN to equivalent levels as controls (Fig-
ures 3C and 3D). In this model we could not detect presentation of
LV-encoded antigen to OVA-speciﬁc T cells in the spleen in any
group (Figure 3E),16 demonstrating that s.c. immunization does not
result in circulation of LV beyond draining LNs. Depletion of DCs
throughout the experiment ablated activation of T cell proliferation
in draining LNs, suggesting that DCs, and not other APCs, were
required to present LV-encoded antigen.
To investigate whether T cells primed by cross-presenting DCs pro-
duced effector cytokines, we transferred OT-I cells and analyzed the
production of interferon g (IFNg) by dividing cells ex vivo. Figures
3F and 3G show that OVA-speciﬁc T cells primed by repopulating
DCs efﬁciently produced IFNg after undergoing several rounds of di-
vision, equivalent to that seen in directly primed T cells. Together,
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Figure 4. Repopulating DCs Prime Endogenous Tumor-Protective T Cells
CD11c.DTR chimeras were immunized with LV:IiOVA with or without DT and
challenged 11 days later by s.c. injection of EG7 tumor cells. (A) Representative
graph from one experiment showing changes in tumor area ± SEM over time post-
injection of tumor in mice immunized with PBS (circles, n = 1) or LV with (squares,
n = 4) or without DT (triangles, n = 4). (B) Summary bar graph showing the tumor
area ± SEM on day 24 post-injection: PBS, n = 3; LV immunization, n = 8; LV im-
munization in DT-injected mice, n = 8. Data are pooled from two independent ex-
periments; p = 0.0363, Kruskal-Wallis test.
Molecular Therapythese data suggest that CD11c+ DCs, which were absent at the point of
immunization, acquire and present LV-encoded antigen to CD8+
T cells that proliferate and accumulate in draining LNs. Furthermore,
cross-presentation of LV-encoded antigen is sufﬁcient to prime
functional IFNg-producing CD8+ effector T cells in vivo.Cross-Presentation of LV-Encoded Antigens by DCs Primes an
Endogenous T Cell Response that Protects Mice from Tumor
Challenge
Our data suggested that after cutaneous immunization, DCs that had
indirectly acquired LV-encoded antigen primed functional CD8+
OT-I T cells. However, presentation of antigen at this time point
will occur in the absence of LV-dependent innate immune activation
signals, which are produced by intact LV particles and upon integra-
tion of LV genes into the host genome.17,25 Presentation of antigen by
DCs that have not been appropriately activated leads to an abortive
T cell response.26–28 Therefore, we questioned whether cross-presen-
tation of LV-encoded antigens by DCs led to the differentiation ofFigure 3. Repopulating DCs Cross-Present Lentiviral Antigen to T Cells In Vivo
(A) Schematic showing the experimental model. CD11c.DTR chimeras received either th
Three days after the first injection of DT, mice were immunized s.c. with PBS or 14 ng R
and immunized mice received CFSE-labeled CD8+ OT-I cells 8 days after immunizat
histograms showing dilution of CFSE in gated live LN OT-I cells. (C) Bar graph showing th
LV + PBS: p = 0.0061; LV + PBS versus LV + noDCs: p = 0.0012; PBS versus LV + repop
Bar graph showing the percentage (left) and number (right) ± SEM of total OT-I cells accu
LV: p = 0.0240; LV versus no DCs: p = 0.0023; PBS versus repopulating DCs: p = 0.008
p = 0.0061; DCs versus no DCs: p = 0.0140; PBS versus LV + repopulating DCs: p = 0.0
frequency of OT-1 cells in the spleens of control and immunized mice. (F) Representative
gated on live OT-I cells. (G) Bar graphs showing the percentage (left) and number (right) ±
0.0061; LV versus no DCs: p = 0.0025; PBS versus repopulating DCs: p = 0.0040; LV v
Number: PBS versus LV: p = 0.0061; LV versus no DCs: p = 0.0025; PBS versus re
repopulating DCs: p = 0.0061 (Mann-Whitney test). Data are pooled from four independ
DCs (n = 8). * p < 0.05; ** p < 0.01; p < 0.001.
508 Molecular Therapy Vol. 25 No 2 February 2017functional endogenous effector T cells that could kill tumor target
cells in vivo. Established CD11c.DTR chimeras were immunized
with 14 ng RT activity of LV:IiOVA and received a short course
of DT treatment to deplete DCs prior to and 5 days after injection
of LV (Figure 3A). The mice were then challenged by injection of
EG7.OVA tumor cells 11 days after immunization, once DC repopu-
lation had occurred. Endogenous T cells control tumor growth less
efﬁciently in BM chimeras than in wild-type mice, and with this
low dose of LV-encoded antigen, are able only to delay tumor growth
in this model. However, the tumor growth was controlled to the same
extent when DCs were present throughout the experiment or repopu-
lated 5 days after immunization (Figure 4). Together, these data sug-
gest that acquisition of LV-encoded antigen by DCs that have not
been exposed to circulating LV particles is sufﬁcient to activate
immunogenic DCs that prime functional endogenous CD8+ T cells.
In this model we could not test a requirement for DCs by injecting
DT throughout the experiment because activated T cells express
CD11c and are killed.DISCUSSION
LVs are powerful antigen delivery agents that prime durable thera-
peutic responses in murine models of cancer. The potency of LV
vaccination has been attributed to the efﬁcient transduction of DCs
and the persistence of LV-encoded antigen in the host. Our data
show that, in addition to directly priming LV-speciﬁc T cells, DCs
may also indirectly acquire and cross-present LV-encoded antigen
from transduced cells, thereby perpetuating the vaccination response.
DCs require direct activation by pathogen-derived molecules to be
licensed to prime effector T cell immunity.28,29 In the absence of these
signals, T cells cannot differentiate into cytokine-producing effectors
and subsequently cannot control tumor growth.27 Therefore, the
priming of functional effector T cells by DCs that have indirectly ac-
quired LV-encoded antigen in our model strongly suggests that DCs
are receiving innate pathogen-derived signals upon uptake of trans-
duced cells. Understanding which LV-derived molecules are required
to activate DC immunity is essential as we engineer next-generation
LVs for use in the clinic.ree or five injections of DT every 2–3 days to ablate DCs over different time periods.
T activity LV-Ii:OVA. To visualize presentation of LV-encoded antigen in vivo, control
ion, and draining LNs and spleens were examined 65 hr later. (B) Representative
e number ± SEM of dividing OT-I cells (gate shown in B) in draining LNs. PBS versus
ulating DCs: p = 0.0040; LV + no DCs versus LV + repopulating DCs: p = 0.0007. (D)
mulating in the draining LNs of control or immunized mice. Percentage: PBS versus
1; LV + no DCs versus LV + repopulating DCs: p = 0.0007. Number: PBS versus LV:
040; LV + DT versus LV + repopulating DCs: p = 0.0080. (E) Bar graph showing the
dot plots showing the percentage of IFNg+ dividing (CFSElow) cells. Cells were pre-
SEM of IFNg+ dividing OT-I cells in the draining LNs. Percentage: PBS versus LV: p =
ersus repopulating DCs: p = 0.0205; no DCs versus repopulating DCs: p = 0.0016.
populating DCs: p = 0.0040; LV versus repopulating DCs: p = 0.1883; DT versus
ent experiments: PBS (n = 4), LV with PBS (n = 7), no DCs (n = 5–6), or repopulating
www.moleculartherapy.orgThe continued acquisition and presentation of LV-encoded antigen
from transduced cells by DCs suggests a mechanism to explain the
prolonged activation of effector T cells in the absence of circulating
LV particles. We propose that cutaneous immunization with LV re-
sults in the direct transduction of migrating DCs that prime the initial
T cell response,11,15 but also provides a reservoir of LV-encoded an-
tigen in longer-lived cells, which is accessed at later time points by
other DCs. However, we have been unable to identify the cellular
LV reservoir because of the low, physiologically relevant LV dose
used in our vaccine. Published data using luciferase-expressing LVs
suggest that transduced cells are rapidly visible both at the immuni-
zation site in the skin and in draining LNs.17 Therefore, we speculate
that, in addition to DCs acquiring LV-encoded antigen from trans-
duced cells in the skin and migrating to LNs, LVs may also drain
directly to LNs after injection, where they are captured by subcapsular
sinus macrophages. This has been demonstrated for other viral parti-
cles.30 Subcapsular sinus macrophages may then provide a source of
LV-encoded antigen directly in LNs. It is also possible that, in addi-
tion to uptake of dying transduced cells, DCsmay also directly receive
LV peptide-MHC I complexes on their surface from living cells, via a
process known as cross-dressing.31,32 An alternative explanation
for our data is that LV immunization targets DC precursors that
are not depleted upon injection of DT. The Collins lab has shown
that intravenous injection of high doses of LV results in persistent
presentation of LV-encoded antigen because of the transduction of
splenic DC precursors that continue to seed the mature DC pool
over time.33 However, DC precursors do not reside in the LNs,34
and we could not detect presentation of LVs in the spleen, suggesting
that splenic cells are not transduced after s.c. immunization with LVs.
Depletion of CD11c+ DCs from the CD11c.DTR mouse is a powerful
tool for determining DC function in vivo,35 but the data obtained us-
ing this model must be carefully interpreted in the light of potential
caveats. Expression of CD11c is not limited to DCs, and treatment
with DT results in the depletion of some other CD11c+ cells, partic-
ularly some macrophages and Ly6Clow monocytes.36,37 Given that
these cells do not migrate to LNs, we believe that depletion of these
other populations does not impact on the T cell response in this
model. We have also demonstrated that loss of DC results in splenic
neutrophilia and a monocytosis, because of an increase in serum
growth factors.38 Expanded monocytes display an activated pheno-
type and have the potential to compensate for DCs under inﬂamma-
tory conditions. However, our data demonstrate a loss of T cell prim-
ing in the continued absence of DCs, suggesting that monocytes do
not contribute to the response after LV vaccination of DT-treated
mice.
Targeting expression of antigens directly to DCs is an attractive
approach for the development of novel immuno-therapeutic pro-
grams.39,40 However, although co-expression of LV-encoded antigens
with molecules that activate DCs enhances the efﬁcacy of LV
immunization,41,42 restricting LVs to DCs can result in reduced im-
mune responses compared with delivery of ubiquitously expressed
antigens,43,44 and Goyvaerts et al.45 recently demonstrated that tar-geting DCs with nanobody-engineered LVs did not enhance immune
responses compared with non-speciﬁc controls. Our data suggest that
protocols that facilitate direct and cross-presentation of LV-encoded
antigens by DCs may be the most effective at priming durable T cell
immunity in patients.
MATERIALS AND METHODS
Mice
Animals were used under protocols approved by local institutional
research committees and in accordance with UK Home Ofﬁce guide-
lines. C57BL/6 (B6) and CD45.1.OT-I TCR transgenic.Rag2/ mice
were bred in-house. CD11c.DTR and b2M/ mice (on the B6 back-
ground) were bought from Jackson Laboratories and bred in-house.
Generation of Syngeneic CD11c.DTR Chimeras
CD11c.DTR syngeneic chimeras were generated as described pre-
viously, and CD11c+ DCs were depleted upon intraperitoneal (i.p.)
injection of 100 ng diphtheria toxin (DT; Sigma) in PBS according
to published protocols.16 Chimeras received either three or ﬁve injec-
tions, once every 48–72 hr, for the short or extended course of deple-
tion, respectively.
Preparation of LV Particles and Immunization of Mice
The LV pSIN-DUAL-empty-Ii:OVA was used for these experiments
cloned from previously described transfer vectors.41 VSV-G-pseudo-
typed LVs were produced as described previously.20,46 LVs were
concentrated 100-fold by ultracentrifugation through a 20% sucrose
cushion in PBS, resuspended in PBS containing 10% glycerol, and
stored as aliquots at80C. The titers of all LVs were determined us-
ing a colorimetric reverse transcriptase (RT) ELISA kit (as described
previously47; Roche). LV stocks for vaccination were diluted in PBS
and injected s.c. at the base of the tail at a dose of 14 ng RT activity
per injection. Direct comparisons of the RT activity of LVs containing
traceable markers, with ﬂow cytometric analysis of transduced 293T
cells, indicated that 14 ng RT activity was the equivalent to injection
of <106 LV particles. For in vitro experiments, pSIN-DUAL-
Thy1.1-Ii:OVA or -GFP were used to allow detection of transduced
cells. These LVs were titered by transduction of 293T cells.
In Vitro LV-Encoded Antigen Presentation Assays
BM-DCs were generated from WT or b2 m/ mice as described
previously.48 Alternatively, BM macrophages were generated from
BM cells seeded at 5 105/mL in 10 mL in non-tissue culture-treated
Petri dishes and were supplemented with 40 ng/mL M-CSF (Pepro-
tech), as described previously.48 Both populations were transduced
on day 6 of culture by adding LV particles directly to the cultures
at a multiplicity of infection of 5–10. Forty-eight hours later, some
cells were analyzed by ﬂow cytometry to conﬁrm transduction.
WT BM-DCs were cultured with LVs for 72 hr, harvested, and
cultured at titrated numbers with 5  104 CFSE-labeled CD8+ OT-I
cells, to test direct presentation of LV-encoded antigen. Co-cultures
were incubated for 65 hr before analysis by ﬂow cytometry. To test
cross-presentation of cell-associated OVA, transduced b2M/
BM-DC cultures were cultured for 48 hr before being washed,Molecular Therapy Vol. 25 No 2 February 2017 509
Molecular Therapyirradiated (1,500 cGy), and co-cultured at titrated numbers with
2.5  104 WT-BM-DCs for 24 hr. CFSE-labeled OT-I cells were
added to the cultures, and the cells were incubated for a further
65 hr before analysis by ﬂow cytometry.
Testing Inactivation of LV Particles
A total of 1  106 GFP-LV particles were irradiated (1,500 cGy) and
cultured at 37C for 48 hr in RPMI 1640 supplemented with 5% heat-
inactivated fetal bovine serum (FBS), L-glutamine, penicillin/strepto-
mycin, and 2-Mercaptoethanol (2-ME). Treated or freshly defrosted
control LVs were added directly to 3T3 cells at an equivalent MOI
(5–10). Three to ﬁve days later, 3T3 cells were tested for transduction
by GFP-expressing LVs by ﬂow cytometry.
Adoptive Transfer of OT-I Cells
To measure antigen presentation in vivo, we injected mice intra-
venously (i.v.) with 4–5  106 CFSE-labeled immune-sorted CD8+
OT-I cells (CD8 T cell kit; Miltenyi Biotec) at deﬁned time points
post-immunization. Sixty-ﬁve hours later, LNs draining the site of in-
jection were harvested and LN cells were stained for ﬂow cytometry.
OT-I cells were identiﬁed by expression of CD8 and the congenic
marker CD45.1, and proliferation was analyzed by dilution of CFSE
among these cells by ﬂow cytometry.
Flow Cytometry
The following mAbs were used: anti-CD8-PE or -allophycocyanin
(clone53-6.7), anti-B220-PE-Cy5 (cloneRA3-6B2), anti-CD45.1-PerCP
(clone A20), anti-CD11c-PE or -allophycocyanin (clone HL3), anti-
H-2Kb-PE (clone AF6-88.5), and anti-IFNg-allophycocyanin
(XMG1.2) from eBioscience or BD Pharmingen. Exclusion of propi-
dium iodide was used to gate on live cells. Intracellular staining of cy-
tokineswasperformedafter overnight ex vivo stimulation of LNcells or
splenocytes with 0.5–5 mMMHC I OVA257–264 peptide. Four hours
before harvesting, brefeldin A (Sigma) was added to the cells at a ﬁnal
concentration of 10 mg/ml. Cells were ﬁxed and permeabilized using
the BD ﬁx and perm kit (BD Biosciences). Non-speciﬁc IFNg produc-
tion by cells restimulated in the absence of antigenwas subtracted from
all samples. Samples were acquired using FACSCalibur or FACScan
ﬂow cytometers (BD Biosciences) and analyzed using FlowJo software
(Tree Star).
Tumor Experiments
Chimeras that had or had not received a short course of DT injections
were immunized with PBS or with 14 ng RT activity of LV-Ii:OVA s.c.
Eleven days later, mice were challenged with 2  106 OVA-trans-
fected EL4 (EG7) thymoma cells injected s.c. into the shaved ﬂank.
Tumor scores were calculated by measuring the width and height
of the tumor at successive time points with a caliper. Mice were killed
when tumor areas exceeded 150 mm2.
Statistical Analysis
Statistical comparisons were made by using parametric or non-para-
metric analyses as appropriate and as speciﬁed in the ﬁgure legends.510 Molecular Therapy Vol. 25 No 2 February 2017AUTHOR CONTRIBUTIONS
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